Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.
Development of novel M1 antagonist scaffolds through the continued optimization of the MLPCN probe ML012.
复制标题
DOI:
10.1016/j.bmcl.2012.06.018
复制
发表时间:
2012-08-01
影响因子:
2.7
通讯作者:
Wood MR
中科院分区:
文献类型:
--
作者:
Melancon BJ;Utley TJ;Sevel C;Mattmann ME;Cheung YY;Bridges TM;Morrison RD;Sheffler DJ;Niswender CM;Daniels JS;Conn PJ;Lindsley CW;Wood MR
This Letter describes the continued optimization of an MLPCN probe molecule M1 antagonist (ML012) through an iterative parallel synthesis approach. After several rounds of modifications of the parent compound, we arrived at a new azetidine scaffold that displayed improved potency while maintaining a desirable level of selectivity over other muscarinic receptor subtypes. Data for representative molecules 7w (VU0452865) and 12a (VU0455691) are presented.
登录
查看更多内容
影响因子:
5
作者:
Heinrich, Julia N.;Butera, John A.;Mayer, Scott C.
通讯作者:
Mayer, Scott C.
影响因子:
4.2
作者:
Kuduk, Scott D.;Chang, Ronald K.;Bilodeau, Mark T.
通讯作者:
Bilodeau, Mark T.
影响因子:
17.7
作者:
Shekhar, Anantha;Potter, William Z.;Felder, Christian C.
通讯作者:
Felder, Christian C.
影响因子:
16.2
作者:
BONNER, TI;YOUNG, AC;BUCKLEY, NJ
通讯作者:
BUCKLEY, NJ
影响因子:
3.6
作者:
Sheffler, Douglas J.;Williams, Richard;Conn, P. Jeffrey
通讯作者:
Conn, P. Jeffrey